Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge
Ascierto PA (1), Brugarolas J (2), Buonaguro L (3), Butterfield LH (4), Carbone D (5), Daniele B (6), Ferris R (7), Fox BA (8), Galon J (9), Gridelli C (10), Kaufman HL (11), Klebanoff CA (12), Melero I (13), Nathan P (14), Paulos CM (15), Ruella M (16), Sullivan R (17), Zarour H (18), Puzanov I (19).
(1) Melanoma, Cancer Immunotherapy and Development Therapeutics Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale, Napoli, Italy. email@example.com.
(2) Kidney Cancer Program, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
(3) Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale, Napoli, Italy.
(4) UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
(5) College of Medicine, James Thoracic Center, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
(6) Department of Oncology, "G. Rummo" Hospital, Benevento, Italy.
(7) Division of Head and Neck Surgery, Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
(8) Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, USA.
(9) National Institute of Health and Medical Research (INSERM), Paris, France.
(10) Unit of Medical Oncology, Hospital "San Giuseppe Moscati", Avellino, Italy.
(11) Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
(12) Center for Cell Engineering and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
(13) Immunology and Immunotherapy Service, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
(14) Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
(15) Department of Microbiology and Immunology Hollings Cancer Center, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA.
(16) Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
(17) Medicine Harvard Medical School and Haematology/Oncology Department, Massachusetts General Hospital, Boston, Massachusetts, USA.
(18) Melanoma Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
(19) Early Phase Clinical Trials Program, Experimental Therapeutics Program, Melanoma Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
Magazine: Journal of Immunotherapy Cancer
Date: Jul 11, 2018Immunology [SP]
Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types.
The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe.
The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise.
The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.
CITATION J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.